BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET

Company Participants

Bruce Mackle - Investor Relations, LifeSci Advisors, LLC

Jay Short - Chairman, Chief Executive Officer and Cofounder

Richard Waldron - Chief Financial Officer

Philippe Martin - Chief Clinical Development and Operations

Conference Call Participants

Brian Cheng - JPMorgan

Kelly Shi - Jefferies

Tony Buter - EF Hutton

Arthur He - H.C. Wainwright

Reni Benjamin - JMP Securities

Operator

Greetings. And welcome to the BioAtla Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen only mode. [Operator Instructions] Please note this conference is being recorded.

I’ll now turn the conference over to your host, Bruce Mackle. You may begin.

Bruce Mackle

Thank you, operator and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; Richard Waldron, Chief Financial Officer. And following today’s call, Philippe Martin, Chief of Clinical Development and Operations; Eric Sievers, Chief Medical Officer and Sheri Lydick, Senior Vice President, Commercial Strategy will be joining Jay and Rick for a short Q&A. Earlier this afternoon, BioAtla released financial results and a business update for the fourth quarter and full year ended December 31, 2022. A copy of the press release is available on the company’s website.

Before we begin, I’d like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla’s business plans and prospects, potential selective licensing collaborations and other strategic partnerships, whether our clinical trials will be potentially registrational, results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans regarding future data updates, clinical trials, regulatory meetings and regulatory submissions, the potential regulatory approval path for our product candidates; expectations about the sufficiency of our cash and cash equivalents and expected R&D and G&A expenses. These statements are subject to various risks, assumptions and uncertainties that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, March 23, 2023, and BioAtla disclaims any obligation to update such statements to reflect future information, events or circumstances, except as required by law.